stockrowHyperfine, Inc.
HYPR Healthcare Medical Devices
Hyperfine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 5.22% from fiscal 2024.
- Revenue
- +44.8%
- EPS
- +25.0%
- Free cash flow
- +13.4%
Quarter to June 2026, against a year earlier
Follow HYPR
Alert me
Hyperfine, Inc. (HYPR) EV/Sales
As of 5 November 2026, Hyperfine, Inc. (HYPR) trades at a EV/Sales of 2.3×. Over the past ten years it has ranged from −121× (March 2022) to 45.4× (April 2022); the current reading is higher than 62% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.3× | 60.95% |
| FY2024 | 2.0× | 366.10% |
| FY2023 | 0.4× | — |
| FY2022 | −8.8× | — |
| FY2021 | −110× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.2× | 23.66% |
| Mar 2026 | 5.0× | 55.14% |
| Dec 2025 | 3.3× | (62.78%) |
| Sep 2025 | 8.7× | 208.00% |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NYXH Nyxoah SA compare | 0.1× |
| OM Outset Medical, Inc. compare | 0.3× |
| LNSR LENSAR, Inc. compare | 1.0× |
| ZOMDF Zomedica Corp. compare | 1.3× |
| ECOR electroCore, Inc. compare | 2.1× |
| HYPR Hyperfine, Inc. | 2.3× |
| LUCD Lucid Diagnostics Inc. compare | 11.3× |
| MBOT Microbot Medical Inc. compare | 15.0× |
| SERA Sera Prognostics, Inc. compare | 641× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)